stockrow
Friday 6 November 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
132.13
2.33
+1.80%
Follow AXSM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
11.18 | 16.33 | 12.22 | 14.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1,021.26) | (384.77) | (418.04) | (487.10) | |
P/B ratio |
91.72 | 152.20 | 158.53 | 102.90 | |
Price to Tangible BV |
167.77 | 373.97 | 2,405.15 | 254.26 | |
EV/Sales |
10.96 | 16.08 | 11.96 | 13.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(115.98) | (175.23) | (119.79) | (95.13) | |
EV/FCF |
(114.80) | (173.53) | (119.35) | (94.64) | |
Quick Ratio |
1.29 | 1.30 | 1.27 | 1.44 | |
Current Ratio |
1.42 | 1.43 | 1.39 | 1.55 | |
Net Debt/EBITDA |
23.79 | 4.14 | 2.98 | 8.20 | |
Debt/Assets |
15.39% | 16.68% | 17.33% | 17.68% | |
Debt/Equity |
1.21 | 1.52 | 2.27 | 1.38 | |
Asset Turnover |
1.16 | 1.11 | 1.08 | 1.01 | |
Operating CF/Net income |
0.74 | 0.64 | 0.32 | 0.65 | |
Capex/Depreciation |
(0.06) | (0.15) | (0.05) | (0.03) | |
Interest Coverage |
(6.43) | (32.24) | (53.47) | (23.00) | |
Research and Development Expense of Revenue |
19.49% | 21.17% | 27.55% | 24.89% | |
Selling, General and Administrative Expense of Revenue |
78.21% | 95.31% | 96.75% | 86.38% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.07 | 0.08 | |
Share Based Compensation of Revenue |
10.15% | 12.43% | 12.26% | 11.60% | |
Graham Net Nets |
0.00 | 0.00 | (0.01) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.66%) | (1.53%) | (2.21%) | (2.02%) | |
Free Cash Flow Yield |
(0.85%) | (0.57%) | (0.82%) | (1.03%) | |
Revenue per Share |
4.95 | 4.22 | 3.73 | 3.94 | |
Operating CF per Share |
(0.18) | (0.64) | (0.40) | (0.37) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.64) | (0.41) | (0.38) | |
Cash per Share |
5.98 | 6.17 | 5.96 | 6.49 | |
Shareholders Equity per Share |
2.01 | 1.61 | 1.07 | 1.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.01 | 1.61 | 1.07 | 1.77 | |
Free Cash Flow |
(9.67) | (33.40) | (20.82) | (18.72) | |
Working Capital |
214.92 | 196.12 | 172.00 | 210.15 | |
Capital Expenditures |
(0.20) | (0.45) | (0.12) | (0.07) | |
Net Current Asset Value |
3.30 | (21.57) | (47.81) | (12.52) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
269.81 | 238.14 | 206.23 | 183.23 | |
Average Payables |
75.15 | 85.30 | 96.18 | 68.77 | |
Average Inventory |
33.18 | 28.16 | 23.92 | 21.84 | |
Average Assets |
748.01 | 700.62 | 655.14 | 629.15 | |
Average Common Equity |
89.58 | 78.19 | 53.90 | 72.65 |
Columns are period end dates · fundamentals updated 6 Nov 2026